文献速递类风湿关节炎脊柱关节炎

开放标签非强制从原研依那西普转换至生物类似药SB4:对照队列研究的六个月结果

Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
PubMed 文献 · Arthritis Rheumatol · 2018-08-06

2016年,642例炎症性风湿病患者通过结构化沟通策略被要求从原研依那西普(ETN)转换至生物类似药SB4,其中635例(99%)同意转换,625例纳入转换队列;2014年600例ETN治疗患者为历史队列。转换队列6个月持续率为90%,历史队列为92%;转换队列停药相对风险显著更高(校正HR 1.57),CRP和DAS28-CRP下降幅度更小,但作者认为差异无临床相关性。

要点

  • 非强制转换后635/642例(99%)同意从原研ETN换用SB4。
  • SB4组6个月持续率90% vs 原研ETN历史队列92%,停药校正HR 1.57(95%CI 1.05-2.36)。
  • 转换队列CRP和DAS28-CRP的6个月下降幅度均小于历史队列,但作者认为差异无临床相关性。

核心结论

  • 采用专门设计的沟通策略进行非强制从原研ETN向生物类似药SB4转换后,转换队列6个月治疗持续率略低、疾病活动度下降幅度略小,但作者认为这些差异无临床相关性。

研究设计与样本

  • 2016年,642例炎症性风湿病患者通过结构化沟通策略(含退出选项)被要求从原研ETN转换至生物类似药SB4;同意转换者纳入转换队列,2014年接受原研ETN治疗的患者为历史队列。
  • 采用Cox回归比较两队列的药物生存,校正年龄、性别、诊断、ETN治疗时长、ETN剂量间隔、传统合成改善病情抗风湿药使用和CRP水平,并用稳健方差估计量处理重复受试者。
  • 还评估了6个月CRP、DAS28-CRP和Bath强直性脊柱炎疾病活动指数变化的校正差异。

主要发现

  • 642例ETN治疗患者中635例(99%)同意转换;转换队列纳入625例(类风湿关节炎433例、银屑病关节炎128例、强直性脊柱炎64例),历史队列纳入2014年600例ETN治疗患者。
  • 生物类似药SB4的6个月粗治疗持续率为90%(95%CI 88-93%),原研ETN的6个月治疗持续率为92%(95%CI 90-94%)。
  • 转换队列较历史队列的停药相对风险显著更高(校正HR 1.57,95%CI 1.05-2.36)。
  • 转换队列较历史队列6个月CRP下降幅度更小(校正差值1.8,95%CI 0.3-3.2),DAS28-CRP下降幅度也更小(校正差值0.15,95%CI 0.05-0.25)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effects of non-mandatory transitioning from the originator biologic drug etanercept (ETN) to its biosimilar, SB4, on drug survival and effectiveness in a controlled cohort study of patients with an inflammatory rheumatic disease. METHODS: In 2016, 642 patients were asked to transition their treatment from originator ETN to biosimilar SB4 by a structured communication strategy with opt-out option. Patients who consented to switch to SB4 were considered eligible for inclusion in the transition cohort, while patients being treated with originator ETN in 2014 were recruited as the historical cohort. Drug survival was compared between the 2 cohorts using Cox regression analyses, which were adjusted for age, sex, diagnosis, ETN treatment duration, ETN dose interval, conventional synthetic disease-modifying antirheumatic drug usage, and C-reactive protein (CRP) level, with a robust variance estimator applied to account for repeated subjects (i.e., patients who were included in both the transition cohort and the historical cohort). Adjusted differences in the 6-month change in CRP level, Disease Activity Score in 28 joints using CRP level (DAS28-CRP), and Bath Ankylosing Spondylitis Disease Activity Index were also assessed. RESULTS: Of the 642 ETN-treated patients, 635 (99%) agreed to transition from originator ETN to biosimilar SB4, of whom 625 patients (433 with rheumatoid arthritis, 128 with psoriatic arthritis, and 64 with ankylosing spondylitis) were included in the transition cohort, and 600 ETN-treated patients from 2014 were included in the historical cohort. The crude treatment persistence rate for biosimilar SB4 over 6 months was 90% (95% confidence interval [95% CI] 88-93%), compared to a 6-month treatment persistence rate of 92% (95% CI 90-94%) for originator ETN. Patients in the transition cohort, compared to the historical cohort, had a statistically significantly higher relative risk of treatment discontinuation (adjusted hazard ratio 1.57, 95% CI 1.05-2.36) and showed smaller decreases in the CRP level (adjusted difference 1.8, 95% CI 0.3-3.2) and DAS28-CRP (adjusted difference 0.15, 95% CI 0.05-0.25) over 6 months. CONCLUSION: Non-mandatory transitioning from originator ETN to biosimilar SB4 using a specifically designed communication strategy resulted in a slightly lower 6-month treatment persistence rate and smaller decreases in disease activity in the transition cohort compared to the historical cohort, but these differences were not considered clinically relevant.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study. Arthritis Rheumatol. 2018. PMID: 29609207. doi:10.1002/art.40516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。